ZA200701231B - Tumor-homing cels engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trial) - Google Patents

Tumor-homing cels engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trial)

Info

Publication number
ZA200701231B
ZA200701231B ZA200701231A ZA200701231A ZA200701231B ZA 200701231 B ZA200701231 B ZA 200701231B ZA 200701231 A ZA200701231 A ZA 200701231A ZA 200701231 A ZA200701231 A ZA 200701231A ZA 200701231 B ZA200701231 B ZA 200701231B
Authority
ZA
South Africa
Prior art keywords
tumor
trial
homing
necrosis factor
cels
Prior art date
Application number
ZA200701231A
Other languages
English (en)
Inventor
Gianni Alessandro Massimo
Carlo-Stella Carmelo
Colotta Francesco
Original Assignee
Dompe Pha R Ma Spa Res & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Pha R Ma Spa Res & Mfg filed Critical Dompe Pha R Ma Spa Res & Mfg
Publication of ZA200701231B publication Critical patent/ZA200701231B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200701231A 2004-07-29 2005-07-21 Tumor-homing cels engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trial) ZA200701231B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (de) 2004-07-29 2004-07-29 Tumor-ansteuernde Zellen, welche "tumor necrosis factor-related apoptosis inducing ligand" (TRAIL) exprimieren

Publications (1)

Publication Number Publication Date
ZA200701231B true ZA200701231B (en) 2008-08-27

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200701231A ZA200701231B (en) 2004-07-29 2005-07-21 Tumor-homing cels engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trial)

Country Status (24)

Country Link
US (1) US20070264231A1 (de)
EP (2) EP1621550A1 (de)
JP (1) JP5042826B2 (de)
KR (1) KR20070047757A (de)
CN (1) CN101076540B (de)
AT (1) ATE455847T1 (de)
AU (1) AU2005266543B2 (de)
BR (1) BRPI0513855A (de)
CA (1) CA2571426A1 (de)
DE (1) DE602005019050D1 (de)
DK (1) DK1771468T3 (de)
ES (1) ES2340400T3 (de)
HR (1) HRP20100227T1 (de)
IL (1) IL180233A (de)
MX (1) MX2007001152A (de)
NO (1) NO20070956L (de)
NZ (1) NZ552223A (de)
PL (1) PL1771468T3 (de)
PT (1) PT1771468E (de)
RS (1) RS51381B (de)
RU (1) RU2390558C2 (de)
SI (1) SI1771468T1 (de)
WO (1) WO2006010558A1 (de)
ZA (1) ZA200701231B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551428A (en) * 2004-06-18 2010-03-26 Genentech Inc Use of apo2L receptor agonists and NK cells or NK cell activators
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
JP5339533B2 (ja) * 2007-05-18 2013-11-13 国立大学法人旭川医科大学 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
CN104160027B (zh) * 2012-02-01 2016-06-22 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
SG11201703326SA (en) 2014-10-24 2017-05-30 Aladar Szalay Combination immunotherapy approach for treatment of cancer
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
DK3421590T3 (da) * 2015-07-29 2021-10-04 Onk Therapeutics Ltd Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
EP3712257A1 (de) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modifizierte natürliche killerzellen mit erhöhter resistenz gegen zelltod
MX2021011373A (es) 2019-03-21 2022-01-06 Onk Therapeutics Ltd Celulas efectoras inmunitarias modificadas con mayor resistencia a la muerte celular.
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
IL132596A0 (en) * 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
AU2001290720A1 (en) * 2000-09-11 2002-03-26 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
WO2002066044A2 (en) * 2000-10-24 2002-08-29 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
DE602005019050D1 (de) 2010-03-11
EP1621550A1 (de) 2006-02-01
RU2390558C2 (ru) 2010-05-27
CN101076540A (zh) 2007-11-21
NO20070956L (no) 2007-02-20
PL1771468T3 (pl) 2010-07-30
AU2005266543B2 (en) 2012-02-02
IL180233A (en) 2010-12-30
HRP20100227T1 (hr) 2010-07-31
RU2007107369A (ru) 2008-09-10
WO2006010558A8 (en) 2006-08-24
JP2008507961A (ja) 2008-03-21
US20070264231A1 (en) 2007-11-15
ES2340400T3 (es) 2010-06-02
KR20070047757A (ko) 2007-05-07
HK1110874A1 (en) 2008-07-25
EP1771468B1 (de) 2010-01-20
IL180233A0 (en) 2007-07-04
EP1771468A1 (de) 2007-04-11
WO2006010558A1 (en) 2006-02-02
BRPI0513855A (pt) 2008-05-20
SI1771468T1 (sl) 2010-07-30
ATE455847T1 (de) 2010-02-15
PT1771468E (pt) 2010-04-20
RS51381B (sr) 2011-02-28
AU2005266543A1 (en) 2006-02-02
NZ552223A (en) 2009-01-31
JP5042826B2 (ja) 2012-10-03
MX2007001152A (es) 2007-04-18
CN101076540B (zh) 2012-10-24
DK1771468T3 (da) 2010-05-25
CA2571426A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
ZA200701231B (en) Tumor-homing cels engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trial)
MX2024010824A (es) Moleculas de union contra bcma y usos de las mismas.
EP4592314A3 (de) Ein- und mehrkettige chimäre polypeptide und verwendungen davon
SA521421744B1 (ar) علاج مناعي توليفي للسرطان
MX2023007644A (es) Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2.
MX2021007939A (es) Porciones de union a claudina 18.2 y usos de estas.
WO2005118825A3 (en) Chimeric adenoviruses for use in cancer treatment
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
IL184617A0 (en) Dr5 antibodies and uses thereof
PH12018550164A1 (en) Bcma binding molecules and methods of use thereof
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
ZA201905462B (en) Proteins binding her2, nkg2d and cd16
MXPA05008319A (es) Compuestos oligomericos para la modulacion de la expresion de survivina.
SG170080A1 (en) Human monoclonal antibodies to o8e
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
WO2018118494A3 (en) Use of car-modified human natural killer cells to treat cancer
IL188594A0 (en) Anti-ccr7 receptor antibodies for the treatment of cancer
WO2011031884A3 (en) Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
WO2020221873A8 (en) Car t-cells targeting bcma and uses thereof
EP4233893A3 (de) Materialien und verfahren zur bindung von siglec-3/cd33
WO2009126817A3 (en) Ige antibodies for the treatment of cancer
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
MX2010006425A (es) Moduladores de proteina cinasa de objetivos multiples 1,3-ciclopentadiona-substituida de cancer, angiogenesis y las trayectorias inflamatorias asociadas con los mismos.